Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AGEN vs XOMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AGEN Captures Overall Composite Edge (52.7 HOLD vs 55.8 HOLD), While XOMA Leads 3–2 on Growth & Valuation Pillars

AGEN Overall Winner 6-Pillar Tally: AGEN 2 – 3 XOMA (1 Tie) Matrix Metrics: AGEN 3 – 7 XOMA

As of Nov 16, 2026, Agenus Inc. (AGEN) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (52.7/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while XOMA wins 3–2 across the 6-pillar growth and valuation breakdown. AGEN trades at $6.34 (3.7x Forward P/E, 38.9% operating margin) versus XOMA at $40.17 (21.5x Forward P/E, -3.9% operating margin).

  • Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. AGEN 52.7/100 HOLD), AGEN captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -3.9% operating margin) and revenue trajectory (+4.1% vs. -22.6% YoY).
  • Technical & Structure Timing Caution: AGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.0); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AGEN vs XOMA
AGEN NASDAQ Head-to-Head Winner
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.34
-5.79% 1D
Market Cap $310.8M
TTM Revenue $34M
Forward P/E 3.7x
Beta / 30D Vol 1.60β · 76% Vol
Unified Composite Score
52.7 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 42
RSI-14: 42.0 · SMA20: $6.73 · SMA50: $7.33
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06

6-Pillar Scorecard Institutional Category Breakdown (AGEN 2 – 3 XOMA)

Columns: Metric · AGEN · XOMA
1. Valuation Multiples AGEN
Forward P/E 3.7x 21.5x
Trailing P/E 29.9x 28.2x
PEG Ratio 1.44x N/M
EV / Revenue 8.9x 16.1x
2. Growth & Scale XOMA
Revenue Growth (YoY) +4.1% -22.6%
Earnings Growth (YoY) -99.0% +207.9%
TTM Revenue (USD) $34M $49M
Market Cap $310.8M $781.8M
3. Profitability & Quality XOMA
Gross Margin N/A 99.0%
Operating Margin 38.9% -3.9%
Net Profit Margin 30.8% 69.6%
Return on Equity (ROE) -1278.8% 34.2%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) -$35M $8.3M EBITDA
Cash Flow Margin -103.7% 17.1% EBITDA Mgn
Net Cash / Leverage $9.3M Net Cash $7.79 Book/Sh · 34.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AGEN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 95.2% (11th %ile) 101.5% (100th %ile)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AGEN (3) vs XOMA (7)
Institutional Metric AGEN XOMA Criterion Row Edge
Market Capitalization
Scale
$310.8M $781.8M Larger Scale XOMA
Trailing P/E Ratio
Valuation
29.9x 28.2x Lower Multiple XOMA
Forward P/E Ratio
Valuation
3.7x 21.5x Lower Multiple AGEN
Revenue Growth (YoY)
Growth
+4.1% -22.6% Higher Growth AGEN
Operating Margin (TTM)
Profitability
38.9% -3.9% Higher Margin AGEN
Net Profit Margin
Profitability
30.8% 69.6% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
-1278.8% 34.2% Higher ROE XOMA
52-Week Range Position
Momentum
48% ($3–$10) 78% ($22–$45) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
1.60β · 76% Vol 0.68β · 37% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
52.7 / 100 (HOLD) 55.8 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$34M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 99.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.44x PEG · 8.9x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$35M ($9.3M Net Cash) $8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AGEN +103.16 pp
AGEN: +99.35% · XOMA: -3.81%
3M Horizon AGEN +45.21 pp
AGEN: +54.55% · XOMA: +9.34%
6M Horizon AGEN +28.94 pp
AGEN: +63.2% · XOMA: +34.26%
1Y Horizon AGEN +16.74 pp
AGEN: +41.34% · XOMA: +24.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AGEN vs XOMA. Trailing 12-month operating profitability (AGEN 38.9% vs XOMA -3.9%) and valuation multiples (AGEN 3.7x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

AGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$34M
Gross MarginN/A
Op. Margin38.9%
ROE / Fwd P/E-1278.8% · 3.7x
XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AGEN BREAKDOWN
33d in phase · OBV NEUTRAL
Current IV 95.2%
IV Percentile 11th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $310.8M market capitalization and 38.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AGEN vs XOMA Key Questions & Quantitative Answers

As of Nov 16, 2026, Agenus Inc. (AGEN) captures the overall head-to-head institutional edge over XOMA Royalty Corporation (XOMA) on higher Unified Composite conviction (52.7/100 HOLD vs. 55.8/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while XOMA wins 3–2 across the 6-pillar growth and valuation breakdown. AGEN trades at $6.34 (3.7x Forward P/E, 38.9% operating margin) versus XOMA at $40.17 (21.5x Forward P/E, -3.9% operating margin). Composite vs. Pillar Nuance: While XOMA currently prints a higher short-term Unified Composite Score (55.8/100 HOLD vs. AGEN 52.7/100 HOLD), AGEN captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -3.9% operating margin) and revenue trajectory (+4.1% vs. -22.6% YoY). Technical & Structure Timing Caution: AGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.0); meanwhile XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XOMA leads the Growth & Scale pillar: AGEN posts +4.1% YoY revenue growth and -99.0% YoY earnings growth on $34M TTM revenue (N/A gross margin, 38.9% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, AGEN generates $34M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, AGEN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.

AGEN screens cheaper on headline valuation multiples. AGEN trades at 3.7x Forward P/E, 29.9x Trailing P/E, 1.44x PEG, and 8.9x EV/Revenue (-103.7% FCF margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AGEN (-1278.8% ROE) versus XOMA (34.2% ROE) capital efficiency.

In options market volatility and institutional positioning, AGEN carries 95.2% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.60β · 76% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.